Reliance Life Sciences Pvt Ltd has received a licence from the Indian Institute of Technology Kanpur for a gene therapy method that has the potential to treat a variety of genetic eye ailments. Reliance Life Sciences will further develop the gene treatment technology from IIT Kanpur into a native product. The science of molecular medicine has recently seen the emergence of gene therapy employing viral vectors as a powerful tool.
Buy Prime Test Series for all Banking, SSC, Insurance & other exams
The patented technology was created by Jayandharan Giridhara Rao and Shubham Maurya from the Department of Biological Sciences and Bioengineering (BSBE), IIT Kanpur, to treat a genetic illness by altering an organism’s gene.
According to IIT Kanpur, this is the first instance in which a gene therapy-related technology has been created and given to a business in India. To meet unmet therapeutic requirements, Reliance Life Sciences is creating a number of different gene treatments. Also, the company is working on a variety of mRNA products and vaccines for both human and animal health.
Human gene therapy aims to change a gene’s expression or the biological characteristics of living cells for therapeutic purposes. Gene therapy is a method for treating or curing disease by changing a person’s DNA. Gene treatments can function in a variety of ways:
Products utilising gene therapy are being investigated for the treatment of diseases like cancer, genetic disorders, and infectious diseases.
You may also read this:
The International Cricket Council has suspended the Cricket Canada membership with the immediate effect. ICC…
Meesho has partnered with the BSE (Bombay Stock Exchange) to launch Project Shikhar. This initiative…
A Tamil Nadu farmer who emerged as the inspiring example of how the sustainable agriculture…
Indian teenagers Vivaan Chhawchharia, Ariana Agarwal, and Avyana Mehta won the 2926 Earth Prize as…
India's seafood sector recorded the highest-ever export performance in both volume and value in the…
Indian fashion star Bhavitha Mandava has secured the in the prestigious Forbes 30 Under 30…